KN- 048 Mono ORR 1
![](https://msdgccpulse.com/wp-content/uploads/sites/82/2024/05/a-key-for-more-tomorrows-for-your-first-line-banner-3.png)
![](https://msdgccpulse.com/wp-content/uploads/sites/82/2024/05/monotherapy-demonstrated-improved-overall-survival-4.png)
References:
- Keytruda® SPC.
- MSD DATA ON FILE KN048- 5-YEAR POSTHOC ANALYSIS SEPTEMBER 28,2022.
- Burtness B, Harrington KJ, Greil R, et al; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019 ;394(10212):1915-1928.
![](https://msdgccpulse.com/wp-content/uploads/sites/82/2024/05/progression-free-survival-with-keytruda-cps-1-2.png)
References:
- Keytruda® SPC.
- MSD DATA ON FILE KN048- 5-YEAR POSTHOC ANALYSIS SEPTEMBER 28,2022.
- Burtness B, Harrington KJ, Greil R, et al; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019 ;394(10212):1915-1928.
![](https://msdgccpulse.com/wp-content/uploads/sites/82/2024/05/keytruda-durability-when-used-as-monotherapy-cps-1.png)
References:
- Keytruda® SPC.
- MSD DATA ON FILE KN048- 5-YEAR POSTHOC ANALYSIS SEPTEMBER 28,2022.
- Burtness B, Harrington KJ, Greil R, et al; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019 ;394(10212):1915-1928.
![](https://msdgccpulse.com/wp-content/uploads/sites/82/2024/05/Artboard-145.png)
References:
- Keytruda® SPC.
- MSD DATA ON FILE KN048- 5-YEAR POSTHOC ANALYSIS SEPTEMBER 28,2022.B
![](https://msdgccpulse.com/wp-content/uploads/sites/82/2024/05/principles-of-systemic-terapy-for-non-nasopharyngeal-cancers.png)
References:
- Keytruda® SPC.
- National Comprehensive Cancer Network. NCCN Guidelines. Version 2.2024. Head and Neck Cancers. Available at:https://www.nccn.org/guidelines/guidelinesprocess/transparency-process-and-recommendations/GetFileFromFile ManagerGuid?FileManagerGuidId=c4edff60-3e93-45d9-8503-5892d71ea8be. Last accessed: 22/4/2024. All rights reserved. content are trademarks owned by the National Comprehensive cancer Network
![](https://msdgccpulse.com/wp-content/uploads/sites/82/2024/05/extended-follow-up-of-5-years-Mono-and-Chemo-therapy-HNSCC-in-patients-CPS-1.png)
References:
- Keytruda® SPC.
- MSD DATA ON FILE KN048- 5-YEAR POSTHOC ANALYSIS SEPTEMBER 28,2022.B
SA-OHN-00027 | Exp: 30 Dec 2024.